SOT Heads Into Results With a Jarring Price History

SOT, Société de Thérapeutique Marocaine, reports on October 30 carrying a sharp one-month loss into a print that has historically punished shareholders.

The stock closed at MAD 320 on October 23, down 11% over the past month despite clawing back nearly 4% across the last week. That recovery trims but does not erase the recent slide. Short interest, options, and analyst data are absent from the available snapshot, so the positioning picture is thin. What the data does carry, however, is a price-reaction history that stands out even among small-cap pharmaceuticals.

The three most recent earnings events have all produced negative returns. The August 2026 print saw the stock fall roughly 1% on the day and hold near flat over five sessions. The September 2026 event was sharper, delivering a 3% one-day drop and a 7.6% loss over the following week. Most striking is the May 2026 cluster, where the stock fell more than 77% on the day and nearly 78% over five sessions, a move severe enough to suggest a structural event rather than a routine earnings miss. The subsequent May 2 filing recorded a flat one-day move but still finished the week down 78%, consistent with a delayed digest of the same shock.

SOT carries a dividend score in the 84th percentile and an earnings yield ranking at the 82nd percentile, suggesting the stock screens as cheap and income-generating relative to its universe. Its sector score, however, sits in the 39th percentile, a reminder that the Moroccan pharmaceutical sector context is less favourable. Dividend history is stale, with the last disclosed payment in June 2022 at MAD 25 per share, down sharply from the MAD 67 paid in 2020 and 2019.

The October 30 print arrives at a moment when the stock has yet to recover from a punishing run of post-earnings declines. The question the result will answer is whether the business fundamentals that underpin the elevated earnings yield can be demonstrated convincingly enough to break that pattern.